Nurse Practitioner in West Point, NE Accepting Medicare
6 Nurse Practitioner nurses found. Showing 1 - 6
 Allison M Bramlet, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 500 E Decatur St, West Point, NE 68788 Phone: 402-372-2477 Fax: 402-372-6770 |
Ms. Pamela H List, APRN Nurse Practitioner - Primary Care Medicare: Accepting Medicare Assignments Practice Location: 500 East Decatur, West Point, NE 68788 Phone: 402-372-2477 Fax: 402-372-6770 |
Mary F Brockmann, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 500 E Decatur St, West Point, NE 68788 Phone: 402-372-6717 |
Miss Abby D Preszler, APRN Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 430 N Monitor St, West Point, NE 68788 Phone: 402-372-6717 |
Alexis A Albrecht, APRN Nurse Practitioner - Psych/Mental Health Medicare: Medicare Enrolled Practice Location: 430 N Monitor St, West Point, NE 68788 Phone: 402-372-6717 |
Julia Eilerts, Nurse Practitioner - Primary Care Medicare: Not Enrolled in Medicare Practice Location: 540 E Washington St, West Point, NE 68788 Phone: 402-372-1118 |
News Archive
Enrollment complete in DOUBle Phase 3 clinical trial of AzaSite Plus and DexaSite for blepharitis
InSite Vision Incorporated today announced that patient enrollment has been completed in the DOUBle Phase 3 clinical trial of AzaSite Plus (ISV-502) and DexaSite (ISV-305) for the treatment of blepharitis.
Analyzing the FDA bill's course: Bipartisanship or something else?
The bipartisan treatment the FDA user fee bill has enjoyed did not fall like manna from heaven. It came at the insistence of the pharmaceutical and medical device industries, the FDA and legislators on both sides of the aisle who agreed early on they would get a deal done. And then actually did it.
FDA authorizes marketing of first SARS-CoV-2 diagnostic test using De Novo premarket review pathway
Today, the U.S. Food and Drug Administration granted marketing authorization of the BioFire Respiratory Panel 2.1 (RP2.1), a diagnostic test for the simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs (NPS) obtained from individuals suspected of COVID-19 and other respiratory tract infections.
EHSI develops new iPhone app to reduce medication errors for senior citizens
Emerging Healthcare Solutions, Inc. announced today that a new breakthrough iPhone app is being developed to dramatically reduce medication errors for senior citizens. Millions of seniors in America take a confusing array of medications to improve their quality of life. When they forget to take their medications or confuse dosage and administration times, they suffer.
› Verified 7 days ago